Clinical proton MR spectroscopy in central nervous system disorders

Gülin Öz, Jeffry R. Alger, Peter B. Barker, Robert Bartha, Alberto Bizzi, Chris Boesch, Patrick J. Bolan, Kevin M. Brindle, Cristina Cudalbu, Alp Dinçer, Ulrike Dydak, Uzay E. Emir, Jens Frahm, Ramón Gilberto González, Stephan Gruber, Rolf Gruetter, Rakesh K. Gupta, Arend Heerschap, Anke Henning, Hoby P. HetheringtonFranklyn A. Howe, Petra S. Hüppi, Ralph E. Hurd, Kejal Kantarci, Dennis W.J. Klomp, Roland Kreis, Marijn J. Kruiskamp, Martin O. Leach, Alexander P. Lin, Peter R. Luijten, Małgorzata Marjańska, Andrew A Maudsley, Dieter J. Meyerhoff, Carolyn E. Mountford, Sarah J. Nelson, Necmettin Pamir, Jullie W. Pan, Andrew C. Peet, Harish Poptani, Harish Poptani, Stefan Posse, Petra J.W. Pouwels, Eva Maria Ratai, Brian D. Ross, Tom W.J. Scheenen, Christian Schuster, Ian C.P. Smith, Brian J. Soher, Ivan Tkáč, Daniel B. Vigneron, Risto A. Kauppinen

Research output: Contribution to journalReview article

207 Citations (Scopus)

Abstract

A large body of published work shows that proton (hydrogen 1 [ 1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

Original languageEnglish (US)
Pages (from-to)658-679
Number of pages22
JournalRadiology
Volume270
Issue number3
DOIs
StatePublished - Mar 5 2014
Externally publishedYes

Fingerprint

Central Nervous System Diseases
Magnetic Resonance Spectroscopy
Metabolic Diseases
Brain Diseases
Demyelinating Diseases
Proton Magnetic Resonance Spectroscopy
Neuroimaging
Brain Neoplasms
Neurodegenerative Diseases
Protons
Hydrogen
Epilepsy
Ischemia
Stroke
Guidelines
Pediatrics
Brain
Research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Öz, G., Alger, J. R., Barker, P. B., Bartha, R., Bizzi, A., Boesch, C., ... Kauppinen, R. A. (2014). Clinical proton MR spectroscopy in central nervous system disorders. Radiology, 270(3), 658-679. https://doi.org/10.1148/radiol.13130531

Clinical proton MR spectroscopy in central nervous system disorders. / Öz, Gülin; Alger, Jeffry R.; Barker, Peter B.; Bartha, Robert; Bizzi, Alberto; Boesch, Chris; Bolan, Patrick J.; Brindle, Kevin M.; Cudalbu, Cristina; Dinçer, Alp; Dydak, Ulrike; Emir, Uzay E.; Frahm, Jens; Gilberto González, Ramón; Gruber, Stephan; Gruetter, Rolf; Gupta, Rakesh K.; Heerschap, Arend; Henning, Anke; Hetherington, Hoby P.; Howe, Franklyn A.; Hüppi, Petra S.; Hurd, Ralph E.; Kantarci, Kejal; Klomp, Dennis W.J.; Kreis, Roland; Kruiskamp, Marijn J.; Leach, Martin O.; Lin, Alexander P.; Luijten, Peter R.; Marjańska, Małgorzata; Maudsley, Andrew A; Meyerhoff, Dieter J.; Mountford, Carolyn E.; Nelson, Sarah J.; Pamir, Necmettin; Pan, Jullie W.; Peet, Andrew C.; Poptani, Harish; Poptani, Harish; Posse, Stefan; Pouwels, Petra J.W.; Ratai, Eva Maria; Ross, Brian D.; Scheenen, Tom W.J.; Schuster, Christian; Smith, Ian C.P.; Soher, Brian J.; Tkáč, Ivan; Vigneron, Daniel B.; Kauppinen, Risto A.

In: Radiology, Vol. 270, No. 3, 05.03.2014, p. 658-679.

Research output: Contribution to journalReview article

Öz, G, Alger, JR, Barker, PB, Bartha, R, Bizzi, A, Boesch, C, Bolan, PJ, Brindle, KM, Cudalbu, C, Dinçer, A, Dydak, U, Emir, UE, Frahm, J, Gilberto González, R, Gruber, S, Gruetter, R, Gupta, RK, Heerschap, A, Henning, A, Hetherington, HP, Howe, FA, Hüppi, PS, Hurd, RE, Kantarci, K, Klomp, DWJ, Kreis, R, Kruiskamp, MJ, Leach, MO, Lin, AP, Luijten, PR, Marjańska, M, Maudsley, AA, Meyerhoff, DJ, Mountford, CE, Nelson, SJ, Pamir, N, Pan, JW, Peet, AC, Poptani, H, Poptani, H, Posse, S, Pouwels, PJW, Ratai, EM, Ross, BD, Scheenen, TWJ, Schuster, C, Smith, ICP, Soher, BJ, Tkáč, I, Vigneron, DB & Kauppinen, RA 2014, 'Clinical proton MR spectroscopy in central nervous system disorders', Radiology, vol. 270, no. 3, pp. 658-679. https://doi.org/10.1148/radiol.13130531
Öz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014 Mar 5;270(3):658-679. https://doi.org/10.1148/radiol.13130531
Öz, Gülin ; Alger, Jeffry R. ; Barker, Peter B. ; Bartha, Robert ; Bizzi, Alberto ; Boesch, Chris ; Bolan, Patrick J. ; Brindle, Kevin M. ; Cudalbu, Cristina ; Dinçer, Alp ; Dydak, Ulrike ; Emir, Uzay E. ; Frahm, Jens ; Gilberto González, Ramón ; Gruber, Stephan ; Gruetter, Rolf ; Gupta, Rakesh K. ; Heerschap, Arend ; Henning, Anke ; Hetherington, Hoby P. ; Howe, Franklyn A. ; Hüppi, Petra S. ; Hurd, Ralph E. ; Kantarci, Kejal ; Klomp, Dennis W.J. ; Kreis, Roland ; Kruiskamp, Marijn J. ; Leach, Martin O. ; Lin, Alexander P. ; Luijten, Peter R. ; Marjańska, Małgorzata ; Maudsley, Andrew A ; Meyerhoff, Dieter J. ; Mountford, Carolyn E. ; Nelson, Sarah J. ; Pamir, Necmettin ; Pan, Jullie W. ; Peet, Andrew C. ; Poptani, Harish ; Poptani, Harish ; Posse, Stefan ; Pouwels, Petra J.W. ; Ratai, Eva Maria ; Ross, Brian D. ; Scheenen, Tom W.J. ; Schuster, Christian ; Smith, Ian C.P. ; Soher, Brian J. ; Tkáč, Ivan ; Vigneron, Daniel B. ; Kauppinen, Risto A. / Clinical proton MR spectroscopy in central nervous system disorders. In: Radiology. 2014 ; Vol. 270, No. 3. pp. 658-679.
@article{b3d61bf32ac14524ab036a54d2963821,
title = "Clinical proton MR spectroscopy in central nervous system disorders",
abstract = "A large body of published work shows that proton (hydrogen 1 [ 1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.",
author = "G{\"u}lin {\"O}z and Alger, {Jeffry R.} and Barker, {Peter B.} and Robert Bartha and Alberto Bizzi and Chris Boesch and Bolan, {Patrick J.} and Brindle, {Kevin M.} and Cristina Cudalbu and Alp Din{\cc}er and Ulrike Dydak and Emir, {Uzay E.} and Jens Frahm and {Gilberto Gonz{\'a}lez}, Ram{\'o}n and Stephan Gruber and Rolf Gruetter and Gupta, {Rakesh K.} and Arend Heerschap and Anke Henning and Hetherington, {Hoby P.} and Howe, {Franklyn A.} and H{\"u}ppi, {Petra S.} and Hurd, {Ralph E.} and Kejal Kantarci and Klomp, {Dennis W.J.} and Roland Kreis and Kruiskamp, {Marijn J.} and Leach, {Martin O.} and Lin, {Alexander P.} and Luijten, {Peter R.} and Małgorzata Marjańska and Maudsley, {Andrew A} and Meyerhoff, {Dieter J.} and Mountford, {Carolyn E.} and Nelson, {Sarah J.} and Necmettin Pamir and Pan, {Jullie W.} and Peet, {Andrew C.} and Harish Poptani and Harish Poptani and Stefan Posse and Pouwels, {Petra J.W.} and Ratai, {Eva Maria} and Ross, {Brian D.} and Scheenen, {Tom W.J.} and Christian Schuster and Smith, {Ian C.P.} and Soher, {Brian J.} and Ivan Tk{\'a}č and Vigneron, {Daniel B.} and Kauppinen, {Risto A.}",
year = "2014",
month = "3",
day = "5",
doi = "10.1148/radiol.13130531",
language = "English (US)",
volume = "270",
pages = "658--679",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical proton MR spectroscopy in central nervous system disorders

AU - Öz, Gülin

AU - Alger, Jeffry R.

AU - Barker, Peter B.

AU - Bartha, Robert

AU - Bizzi, Alberto

AU - Boesch, Chris

AU - Bolan, Patrick J.

AU - Brindle, Kevin M.

AU - Cudalbu, Cristina

AU - Dinçer, Alp

AU - Dydak, Ulrike

AU - Emir, Uzay E.

AU - Frahm, Jens

AU - Gilberto González, Ramón

AU - Gruber, Stephan

AU - Gruetter, Rolf

AU - Gupta, Rakesh K.

AU - Heerschap, Arend

AU - Henning, Anke

AU - Hetherington, Hoby P.

AU - Howe, Franklyn A.

AU - Hüppi, Petra S.

AU - Hurd, Ralph E.

AU - Kantarci, Kejal

AU - Klomp, Dennis W.J.

AU - Kreis, Roland

AU - Kruiskamp, Marijn J.

AU - Leach, Martin O.

AU - Lin, Alexander P.

AU - Luijten, Peter R.

AU - Marjańska, Małgorzata

AU - Maudsley, Andrew A

AU - Meyerhoff, Dieter J.

AU - Mountford, Carolyn E.

AU - Nelson, Sarah J.

AU - Pamir, Necmettin

AU - Pan, Jullie W.

AU - Peet, Andrew C.

AU - Poptani, Harish

AU - Poptani, Harish

AU - Posse, Stefan

AU - Pouwels, Petra J.W.

AU - Ratai, Eva Maria

AU - Ross, Brian D.

AU - Scheenen, Tom W.J.

AU - Schuster, Christian

AU - Smith, Ian C.P.

AU - Soher, Brian J.

AU - Tkáč, Ivan

AU - Vigneron, Daniel B.

AU - Kauppinen, Risto A.

PY - 2014/3/5

Y1 - 2014/3/5

N2 - A large body of published work shows that proton (hydrogen 1 [ 1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

AB - A large body of published work shows that proton (hydrogen 1 [ 1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.

UR - http://www.scopus.com/inward/record.url?scp=84895440282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895440282&partnerID=8YFLogxK

U2 - 10.1148/radiol.13130531

DO - 10.1148/radiol.13130531

M3 - Review article

C2 - 24568703

AN - SCOPUS:84895440282

VL - 270

SP - 658

EP - 679

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -